Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018;10(2):35-40.
doi: 10.1007/s12609-018-0274-y. Epub 2018 Apr 16.

Immunotherapy in Breast Cancer: the New Frontier

Zishuo I Hu  1 , Heather L McArthur  2
Affiliations
Review

Immunotherapy in Breast Cancer: the New Frontier

Zishuo I Hu et al. Curr Breast Cancer Rep. 2018.

Abstract

Purpose of review: This review summarizes current immunotherapies in breast cancer, with an emphasis on immune checkpoint inhibitors and vaccines.

Recent findings: Combination immunotherapy with checkpoint inhibitors and cytotoxic therapies have shown promising results. Active clinical trials are ongoing in both early stage and metastatic settings for triple negative, HER2+, and hormone-positive breast cancer patients.

Summary: Ongoing challenges remain in defining biomarkers that predict response to immunotherapy, determining the optimal combination immunotherapies, and enhancing the immunogenicity of breast cancer subtypes.

Keywords: Breast cancer; Checkpoint inhibitors; Immunotherapy; Vaccines.

PubMed Disclaimer

Conflict of interest statement

Compliance with Ethical StandardsThe authors declare that they have no competing interests.This article does not contain any studies with human or animal subjects performed by any of the authors.

References

    1. O’Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science. 2010;327:1098–1102. doi: 10.1126/science.1178334. - DOI - PMC - PubMed
    1. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734–1736. doi: 10.1126/science.271.5256.1734. - DOI - PubMed
    1. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24:207–212. doi: 10.1016/j.coi.2011.12.009. - DOI - PMC - PubMed
    1. Vonderheide RH, LoRusso PM, Khalil M, et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res: Off J Am Assoc Cancer Res. 2010;16:3485–3494. doi: 10.1158/1078-0432.CCR-10-0505. - DOI - PubMed
    1. McArthur HL, Diab A, Page DB, et al. A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling. Clin Cancer Res: Off J Am Assoc Cancer Res. 2016;22:5729–5737. doi: 10.1158/1078-0432.CCR-16-0190. - DOI - PMC - PubMed

LinkOut - more resources